Physician profile
Matthew Studebaker
NPI 1487752531
$2,696.23
in general payments reported to CMS, 2019-2025
29 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $170 · 2021: $329 · 2022: $369 · 2023: $600 · 2024: $490 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.51 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $277.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $239.76 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $181.92 | 2019-2024 | Farxiga |
| Abbott Laboratories | $165.54 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $160.65 | 2019-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $120.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $119.66 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.42 | 2021-2024 | Xifaxan |
| Pfizer INC. | $97.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.97 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $79.63 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.11 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $67.74 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Biohaven Pharmaceuticals, INC. | $50.02 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $44.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.55 | 2019-2023 | Xarelto |
| Medtronic, INC. | $33.51 | 2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $28.31 | 2019-2022 | |
| Intuitive Surgical, INC. | $28.28 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.51 | 2021-2022 | |
| Insulet Corporation | $26.07 | 2025 | Omnipod |
| Axsome Therapeutics, INC. | $25.37 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $21.94 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $21.37 | 2025 | Inspire |
| Vanda Pharmaceuticals INC. | $16.54 | 2025 | Fanapt |
| Verona Pharma, INC. | $15.38 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $14.12 | 2024 | Yupelri |
| Kyowa Kirin, INC. | $13.44 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Studebaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.